Clinical Trial Update: Iron Balance Study of DFO and GT56-252 in Patients With Transfusional Iron Overload Secondary to Beta-Thalassemia [Phase 1, Phase 2]

View source ↗

Summary

The document reports the completion of a Phase 1/2 iron balance study evaluating deferoxamine (DFO) and GT56-252 in transfusional iron overload associated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia

Drugs mentioned

• Deferoxamine (deferoxamine)
• GT56-252

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Beta-Thalassemia | Phase 1, Phase 2 | Status: COMPLETED